Commitments to our Clients

Helping Them Close the Right Strategic Transactions

Bring strategic judgement to every key transaction decision

Leverage trusted decision-maker relationships and disciplined execution

Our clients are deal-makers who are ready to use strategic transactions to create value for their company, shareholders, and patients worldwide

  • Our success is measured by the long-term value we create for our clients and the patients they serve
  • We believe that patients around the world deserve access to medicine at a cost they can afford
  • Our charitable work in Africa reflects our desire to help people reach their long-term potential
  • We operate globally, offering the best combination of local knowledge and global reach

Strategic Mandates Across The Full Transaction Spectrum.

KYBORA helps biopharma CEOs navigate M&A, private placements, licensing, and strategic decisions with operator-level industry insights, trusted access to decision-makers, and senior-led execution.

Explore All Services

Mergers & Acquisitions

Sell-side, buy-side, divestitures, and carve-outs. Including complex cross-border situations and contested processes.

Explore

Global Licensing

Maximizing the value of your products globally. Asset and platform deals across markets, sequenced or simultaneous. Counterparty selection grounded in industry knowledge of who can transact and who will.

Explore

Capital Raising

Through KYBORA Capital LLC, our FINRA-registered broker-dealer - including partnership with larger banks on larger transactions. Equity, debt, and structured capital aligned to the strategic plan

Explore

Strategic Advisory

We pair advisory expertise with real commercial, strategic, operational, and transactional experience in life sciences. We give you grounded, industry-tested recommendations - and work alongside you to define your next sources of growth.

Explore

Trusted by Industry Leaders 

Experience includes transactions completed by team members at prior firms

Our Transactions

Sale of Priority Review Voucher to
Sell-side advisor for the divestiture of a Priority Review Voucher to argenx, closed in six weeks
Licensing of Bersiporocinto CS Pharma
Advisor to Daewoong on the out-licensing of its early-stage IPF compound to CS Pharma for $336M
R&D
Collaboration with
Advisor to Raya Therapeutic on its capital raise and R&D collaboration with argenx for an ALS platform trial
$35,000,000 Equity financing
Sell-side advisor on Symbiomix’s $35M Series A from OrbiMed and F-Prime for a differentiated infectious disease compound
Due Diligence $22,000,000 Series B Fundraising
Due diligence advisor on Novadip Biosciences’ €40M Series B for its bone regeneration platform
$46,500,000 Acquisition financing
Advisor to Woodward Pharma on a $125M acquisition financing from a syndicate led by Colbeck Capital Management
Sale of Solosec to
Exclusive sell-side advisor to Lupin on the divestiture of its U.S. Women’s Health business to Evofem for up to $84M
Out-Licensing of Ranibizumab Biosimilar to
Advisor to STADA on the out-licensing of its ranibizumab (Lucentis) biosimilar to Bausch Health
Load More
Sale of Solosec to
Exclusive sell-side advisor to Lupin on the divestiture of its U.S. Women’s Health business to Evofem for up to $84M
Sale of Priority Review Voucher to
Sell-side advisor for the divestiture of a Priority Review Voucher to argenx, closed in six weeks
Sale of CDMO Business to
Acquisition of
Acquisition of
Acquired By
$105,000,000 Strategic investment form
$65,700,000 Pharma asset M&A Coreg®, Coreg® CR, Other
Load More
Out-Licensing of Ranibizumab Biosimilar to
Advisor to STADA on the out-licensing of its ranibizumab (Lucentis) biosimilar to Bausch Health
Licensing of Bersiporocinto CS Pharma
Advisor to Daewoong on the out-licensing of its early-stage IPF compound to CS Pharma for $336M
Global Out-Licensing of CNS asset (ACT-01) to
In-Licensing of Innotox® from
Out-Licensing of CEstrogel® to
Out-Licensing of HLX01 Rituximab Biosimilar to
License of Single Chain Antibody Patent portfolio research to
Out-Licensing of BiTE® antibody to
Load More
$46,500,000 Acquisition financing
Advisor to Woodward Pharma on a $125M acquisition financing from a syndicate led by Colbeck Capital Management
Due Diligence $22,000,000 Series B Fundraising
Due diligence advisor on Novadip Biosciences’ €40M Series B for its bone regeneration platform
$35,000,000 Equity financing
Sell-side advisor on Symbiomix’s $35M Series A from OrbiMed and F-Prime for a differentiated infectious disease compound
R&D
Collaboration with
Advisor to Raya Therapeutic on its capital raise and R&D collaboration with argenx for an ALS platform trial
$25,000,000 Acquisition financing
$16,500,000 Pharma royalty financing
$27,000,000 Acquisition financing
$5,000,000 Acquisition financing
Load More

The above testimonials may not be representative of the experience of other customers and is no guarantee of future performance or success.

Contact Us

Our team is passionate about helping our clients succeed.